Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Investing in real estate is a cornerstone of wealth for a majority of Aussies, but before getting started you should ask yourself this.

Several ASX companies are developing and providing technologies for reliable communications in remote areas, including Harvest Technology.

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.